Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK2 | P51955 | 1/20 | 0.49 |
| ▸ | ATR | Q13535 | 7/20 | 0.47 |
| ▸ | PRKDC | P78527 | 2/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29519952 | 0.76 | ATR (0.56) | NEK2ATRPRKDCTLR9ADORA2A | |
| SCHEMBL12489014 | 0.76 | ATR (0.56) | NEK2ATRPRKDCTLR9ADORA2A | |
| SCHEMBL28283878 | 0.74 | ADORA2A (0.48) | TLR9ADORA2AADORA1KDM4EMEN1 | |
| SCHEMBL32688927 | 0.73 | ATR (0.66) | ATRPRKDCTLR9 | |
| SCHEMBL6701248 | 0.73 | ATR (0.66) | ATRPRKDCTLR9 | |
| SCHEMBL2681285 | 0.72 | SMN1; SMN2 (0.51) | NEK2ATRPRKDCTLR9ADORA2A | |
| SCHEMBL16629029 | 0.72 | ATR (0.51) | NEK2ATRPRKDCTLR9ADORA2A | |
| SCHEMBL31638393 | 0.72 | ATR (0.51) | NEK2ATRPRKDCTLR9ADORA2A | |
| SCHEMBL934804 | 0.72 | ATR (0.51) | NEK2ATRPRKDCTLR9ADORA2A | |
| SCHEMBL10007939 | 0.71 | NEK2 (0.44) | NEK2ATRPRKDCTLR9PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028662-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORP (US) | 2026-01-29 | — | — | US | disclosed |
| US-12435354-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | PROMEGA CORPORATION (US) | 2025-10-07 | — | — | US | disclosed |
| US-12215375-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | PROMEGA CORPORATION (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240158831-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORPORATION | 2024-05-16 | — | — | US | disclosed |
| US-11661623-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | PROMEGA CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-20220348983-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORPORATION | 2022-11-03 | — | — | US | disclosed |
| CN-106148362-B | Novel coelenterazine substrates and methods of use thereof | 普罗梅加公司 | 2021-04-30 | — | — | CN | disclosed |
| US-20200399676-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORPORATION | 2020-12-24 | — | — | US | disclosed |
| US-10774364-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | PROMEGA CORPORATION (US) | 2020-09-15 | — | — | US | disclosed |
| EP-3498710-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | Promega Corporation (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20140223590-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | Promego Corporation (US) | 2014-08-07 | — | — | US | disclosed |
| US-8669103-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | PROMEGA CORPORATION (US) | 2014-03-11 | — | — | US | disclosed |
| CN-103443121-A | Novel coelenterazine substrates and methods of use thereof | PROMEGA CORP | 2013-12-11 | — | — | CN | disclosed |
| CN-103370319-A | Novel coelenterazine substrates and methods of use | PROMEGA CORP | 2013-10-23 | — | — | CN | disclosed |
| EP-2635582-A1 | NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE | Promega Corporation (US) | 2013-09-11 | — | — | EP | disclosed |
| EP-2635595-A2 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | Promega Corporation (US) | 2013-09-11 | — | — | EP | disclosed |
| US-20120174242-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-07-05 | — | — | US | disclosed |
| WO-2012061529-A1 | NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE | PROMEGA CORPORATION (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012061530-A2 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORPORATION (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20120117667-A1 | NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120117667-A1 | NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE | RNGTT, UPF1, NSUN2 | NEK2 2595/4885ATR 3357/4885PRKDC 1562/4885 |
| US-12435354-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | RNGTT, UPF1, LUC7L2 | NEK2 3194/4885ATR 2985/4885PRKDC 1431/4885 |
| US-10774364-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | RNGTT, UPF1, LUC7L2 | NEK2 3194/4885ATR 2985/4885PRKDC 1431/4885 |
| US-20220348983-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | RNGTT, UPF1, LUC7L2 | NEK2 3194/4885ATR 2985/4885PRKDC 1431/4885 |
| US-20240158831-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | RNGTT, UPF1, LUC7L2 | NEK2 3194/4885ATR 2985/4885PRKDC 1431/4885 |
| US-11661623-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | RNGTT, UPF1, LUC7L2 | NEK2 3194/4885ATR 2985/4885PRKDC 1431/4885 |
| US-12215375-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | RNGTT, UPF1, LUC7L2 | NEK2 3194/4885ATR 2985/4885PRKDC 1431/4885 |
| US-20260028662-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | RNGTT, VIP, PREP | NEK2 3197/4885ATR 3155/4885PRKDC 1204/4885 |
| US-20200399676-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | RNGTT, UPF1, LUC7L2 | NEK2 3194/4885ATR 2985/4885PRKDC 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.